Cowen & Co. analyst Boris Peaker downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Market Perform.
Cowen & Co. Downgrades CytomX Therapeutics to Market Perform
Cowen & Co. analyst Boris Peaker downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Market Perform.
Related Posts
Stephens & Co. Maintains Overweight on Baker Hughes, Lowers Price Target to $32
Stephens & Co. analyst Cameron Lochridge maintains Baker Hughes (NASDAQ:BKR) with a Overweight and lowers the price target from $40 to $32.
Picnic With The Hottest New Cannabis Products: Signature Strains, Vapes, K. Haring Glass Testers & More
Discover the latest and most exciting cannabis products in this round-up from Benzinga. Our selection features a wide range of offerings that have recently hit the market, providing something for every cannabis enthusiast.
Why Save Foods Stock Is Blasting Higher
Save Foods, Inc. (NASDAQ: SVFD) shares are trading higher Thursday after the company highlighted its targeting of the U.S. carbon credit market.